Clinical Trial

Effects of a Probiotic in Hypertension

Study acronym: HYPRO
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2024 (before its estimated September 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
High blood pressure is a major risk factor for cardiovascular events, including stroke, heart and kidney failure. Typical anti-hypertensive drugs target vessels, the kidneys or the heart. Here we propose a randomized, placebo-controlled study to test the blood pressure-lowering effect of a probiotic in 110 patients with grade 1 hypertension. In addition, we will investigate glucose variability, fecal bacterial metabolome, peripheral blood effector T cell frequencies (%) and health-related quality of life.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT03906578
Lead Sponsor Charite University, Berlin, Germany
Conditions Hypertension
Enrollment 46 participants
Start Date 2019-09-02
Primary Completion 2024-09-01 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-09